GlassScriptPhysician profile
David S Rudolph
NPI 1881836013
$5,046.64
in general payments reported to CMS, 2019-2025
35 companies · $1,264 in 2025
The $1,264 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $835 · 2020: $217 · 2021: $378 · 2022: $416 · 2023: $684 · 2024: $1,253 · 2025: $1,264.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,182 · Education: $19.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,181.95 |
| Education | $19.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,357.54 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $586.58 | 2019-2025 | Xifaxan |
| Janssen Biotech, INC. | $416.72 | 2019-2025 | Tremfya, Stelara |
| Braintree Laboratories, INC. | $372.39 | 2019-2025 | Suflave, Sutab |
| Takeda Pharmaceuticals U.S.A., INC. | $219.29 | 2019-2025 | Entyvio, Gattex |
| Ardelyx, INC. | $218.88 | 2024-2025 | Ibsrela |
| Pfizer INC. | $190.90 | 2019-2025 | |
| Genzyme Corporation | $174.71 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $155.58 | 2023-2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $151.23 | 2019-2025 | Ocaliva |
| Merck Sharp & Dohme LLC | $141.91 | 2019-2024 | Dificid |
| Gilead Sciences, INC. | $141.90 | 2019-2025 | Epclusa |
| Phathom Pharmaceuticals, INC. | $130.25 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $84.97 | 2024-2025 | Omvoh |
| Madrigal Pharmaceuticals | $77.43 | 2024-2025 | Rezdiffra, Resmetirom |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Romark Laboratories, Lc | $71.72 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $68.89 | 2024-2025 | Iqirvo |
| Qol Medical, LLC | $66.49 | 2024 | Sucraid |
| Ironwood Pharmaceuticals, INC | $61.65 | 2019-2024 | |
| Celgene Corporation | $37.11 | 2023-2024 | Zeposia |
| Aimmune Therapeutics, INC. | $30.93 | 2024-2025 | Vowst |
| Mauna Kea Technologies, INC. | $29.48 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $29.10 | 2023 | Zeposia |
| Ferring Pharmaceuticals INC. | $26.72 | 2022 | |
| Axonics, INC. | $25.73 | 2024 | Axonics |
| Allergan, INC. | $23.02 | 2019-2020 | |
| Biocon Biologics INC | $21.72 | 2025 | Yesintek |
| Orphalan INC | $20.75 | 2025 | Cuvrior |
| Celltrion USA INC. | $19.07 | 2024 | Zymfentra |
| Olympus America INC. | $18.49 | 2024 | Endoclot Phs, Gastrointestinal Videoscope |
| Redhill Biopharma INC. | $17.70 | 2020 | |
| Daiichi Sankyo INC. | $16.39 | 2019 | |
| Esperion Therapeutics, INC. | $14.86 | 2020 | |
| Shionogi INC | $13.34 | 2019 | |
| Alfasigma USA, INC. | $13.20 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Rudolph listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.